OBJECTIVE: Cytokines have an important role in both the initiation and perpetuation of viral myocarditis. Because a causative therapy of myocarditis is not yet well established and immunomodulation is a promising approach, the influence of interleukin (IL)-15, a proinflammatory cytokine, on the course of experimental myocarditis in Coxsackievirus B3 (CVB3)-infected mice was examined. METHODS: Hearts from CVB3-infected (n=14), sham-infected (n=14) and CVB3-infected BALB/c mice treated with IL-15 (n=6) or a competitive IL-15 fusion protein (n=6) were analyzed for hemodynamic function, cellular infiltrates and myocardial collagen content. RESULTS: Induction of myocarditis was associated with significant loss of body and heart weight, decreased left ventricular function, and increased collagen content and cellular infiltrates in the myocardium. Treatment of infected animals with IL-15 resulted in normalization of body and heart weight, and significantly improved systolic and diastolic left ventricular function, comparable with that of uninfected animals. This was paralleled by a significant reduction of myocardial collagen content to levels observed in animals without disease and by markedly reduced cellular infiltration of lymphocytes and macrophages in the myocardium. Inhibition of intrinsic IL-15 with IL-15 fusion protein tended to aggravate the disease. CONCLUSIONS: Treatment with IL-15 has a positive effect on CVB3- induced murine myocarditis and seems to be a promising approach to modifying clinical course, hemodynamics and histopathology of virus-induced myocarditis. Further studies are needed to identify the underlying mechanisms.
OBJECTIVE: Cytokines have an important role in both the initiation and perpetuation of viral myocarditis. Because a causative therapy of myocarditis is not yet well established and immunomodulation is a promising approach, the influence of interleukin (IL)-15, a proinflammatory cytokine, on the course of experimental myocarditis in Coxsackievirus B3 (CVB3)-infected mice was examined. METHODS: Hearts from CVB3-infected (n=14), sham-infected (n=14) and CVB3-infected BALB/c mice treated with IL-15 (n=6) or a competitive IL-15 fusion protein (n=6) were analyzed for hemodynamic function, cellular infiltrates and myocardial collagen content. RESULTS: Induction of myocarditis was associated with significant loss of body and heart weight, decreased left ventricular function, and increased collagen content and cellular infiltrates in the myocardium. Treatment of infected animals with IL-15 resulted in normalization of body and heart weight, and significantly improved systolic and diastolic left ventricular function, comparable with that of uninfected animals. This was paralleled by a significant reduction of myocardial collagen content to levels observed in animals without disease and by markedly reduced cellular infiltration of lymphocytes and macrophages in the myocardium. Inhibition of intrinsic IL-15 with IL-15 fusion protein tended to aggravate the disease. CONCLUSIONS: Treatment with IL-15 has a positive effect on CVB3- induced murinemyocarditis and seems to be a promising approach to modifying clinical course, hemodynamics and histopathology of virus-induced myocarditis. Further studies are needed to identify the underlying mechanisms.
Authors: Crescent L Combe; Magali M Moretto; Joseph D Schwartzman; Jason P Gigley; David J Bzik; Imtiaz A Khan Journal: Proc Natl Acad Sci U S A Date: 2006-04-13 Impact factor: 11.205
Authors: Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: Mei Sun; Manyin Chen; Fayez Dawood; Urszula Zurawska; Jeff Y Li; Thomas Parker; Zamaneh Kassiri; Lorrie A Kirshenbaum; Malcolm Arnold; Rama Khokha; Peter P Liu Journal: Circulation Date: 2007-03-12 Impact factor: 29.690
Authors: Anna Hryniewicz; David A Price; Marcin Moniuszko; Adriano Boasso; Yvette Edghill-Spano; Sadie M West; David Venzon; Monica Vaccari; Wen-Po Tsai; Elzbieta Tryniszewska; Janos Nacsa; Francois Villinger; Aftab A Ansari; Christopher J Trindade; Michel Morre; David Brooks; Philip Arlen; Helen J Brown; Christina M R Kitchen; Jerome A Zack; Daniel C Douek; Gene M Shearer; Mark G Lewis; Richard A Koup; Genoveffa Franchini Journal: J Immunol Date: 2007-03-15 Impact factor: 5.422
Authors: S G Fonseca; M M Reis; V Coelho; L G Nogueira; S M Monteiro; E C Mairena; F Bacal; E Bocchi; L Guilherme; X X Zheng; F Y Liew; M L Higuchi; J Kalil; E Cunha-Neto Journal: Scand J Immunol Date: 2007 Aug-Sep Impact factor: 3.487
Authors: Jared F Purton; Joyce T Tan; Mark P Rubinstein; David M Kim; Jonathan Sprent; Charles D Surh Journal: J Exp Med Date: 2007-04-09 Impact factor: 14.307
Authors: Thomas Wurster; Catharina Pölzelbauer; Tanja Schönberger; Angela Paul; Peter Seizer; Konstantinos Stellos; Andreas Schuster; Rene M Botnar; Meinrad Gawaz; Boris Bigalke Journal: PLoS One Date: 2012-03-15 Impact factor: 3.240